Skip to Content
MilliporeSigma
All Photos(1)

Documents

Y0001006

Dydrogesterone impurity B

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Pregna-4,6-diene-3,20-dione

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C21H28O2
CAS Number:
1162-56-7
Molecular Weight:
312.45
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

dydrogesterone

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4-5,12,16-19H,6-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1

InChI key

JGMOKGBVKVMRFX-LEKSSAKUSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Dydrogesterone impurity B EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Tea Lanišnik Rižner et al.
Steroids, 76(6), 607-615 (2011-03-08)
Dydrogesterone is widely used for menstrual disorders, endometriosis, threatened and habitual abortion and postmenopausal hormone replacement therapy. Although progestins have a promiscuous nature, dydrogesterone does not have clinically relevant androgenic, estrogenic, glucocorticoid or mineralocorticoid activities. To date, systematic biochemical characterization
Julie Brown et al.
The Cochrane database of systematic reviews, 3(3), CD002122-CD002122 (2012-03-16)
Endometriosis is a chronic inflammatory condition defined by the presence of glands and stroma outside the uterine cavity. It occurs in 7% to 10% of all women of reproductive age and may present as pain or infertility. The pelvic pain
Zahiruddin Othman et al.
Menopause (New York, N.Y.), 18(11), 1219-1224 (2011-09-20)
The aim of this study was to evaluate the verbal learning and memory performance of postmenopausal women who received tualang honey (Agro Mas) in comparison with women receiving estrogen plus progestin therapy and untreated controls. A total of 102 postmenopausal
A R Genazzani et al.
Climacteric : the journal of the International Menopause Society, 14(6), 661-668 (2011-09-29)
Sexual desire is affected by endocrine and psychosocial factors. Menopausal hormonal changes are relevant to the causes of sexual dysfunction during reproductive aging. To evaluate the effects of different types of hormonal replacement therapy (HRT) on sexual function, frequency of
A J Scheen et al.
Revue medicale de Liege, 66(4), 209-214 (2011-06-07)
Femoston Low is a hormone replacement therapy that combines low dosages of steroids, i.e. 0.5 mg of estradiol and 2.5 mg of dydrogesterone. This oral preparation should be taken continuously to treat climacteric symptoms in menopausal women. Femoston Low is
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service